{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T12:39:06Z","timestamp":1742647146891,"version":"3.40.1"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T00:00:00Z","timestamp":1732665600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T00:00:00Z","timestamp":1732665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neuropsychopharmacol."],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1038\/s41386-024-02031-w","type":"journal-article","created":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T09:02:16Z","timestamp":1732698136000},"page":"808-817","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Longevity, enhanced memory, and altered density of dendritic spines in hippocampal CA3 and dentate gyrus after hemizygous deletion of Pde\ufeff\ufeff2a in mice"],"prefix":"10.1038","volume":"50","author":[{"given":"Karsten","family":"Baumg\u00e4rtel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola J.","family":"Broadbent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hailing","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brittany","family":"Masatsugu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karly P.","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert W.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea L.","family":"Green","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana K.","family":"Hornberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Petroski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roderick","family":"Scott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Peters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,27]]},"reference":[{"key":"2031_CR1","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1038\/s41573-019-0033-4","volume":"18","author":"GS Baillie","year":"2019","unstructured":"Baillie GS, Tejeda GS, Kelly MP. Therapeutic targeting of 3\u2019,5\u2019-cyclic nucleotide phosphodiesterases: inhibition and beyond. Nat Rev. Drug Discov. 2019;18:770\u201396.","journal-title":"Nat Rev. Drug Discov"},{"key":"2031_CR2","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.neubiorev.2018.02.007","volume":"87","author":"PRA Heckman","year":"2018","unstructured":"Heckman PRA, Blokland A, Bollen EPP, Prickaerts J. Phosphodiesterase inhibition and modulation of corticostriatal and hippocampal circuits: clinical overview and translational considerations. Neurosci Biobehav Rev. 2018;87:233\u201354.","journal-title":"Neurosci Biobehav Rev"},{"key":"2031_CR3","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nrd4228","volume":"13","author":"DH Maurice","year":"2014","unstructured":"Maurice DH, Ke H, Ahmad F, Wang Y, Chung J, Manganiello VC. Advances in targeting cyclic nucleotide phosphodiesterases. Nat Rev Drug Discov. 2014;13:290\u2013314.","journal-title":"Nat Rev Drug Discov"},{"key":"2031_CR4","doi-asserted-by":"publisher","first-page":"13260","DOI":"10.1073\/pnas.192374899","volume":"99","author":"SE Martinez","year":"2002","unstructured":"Martinez SE, Wu AY, Glavas NA, Tang XB, Turley S, Hol WG, et al. The two GAF domains in phosphodiesterase 2A have distinct roles in dimerization and in cGMP binding. Proc Natl Acad Sci. USA. 2002;99:13260\u20135.","journal-title":"Proc Natl Acad Sci. USA"},{"key":"2031_CR5","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1016\/S0021-9258(19)68134-2","volume":"257","author":"TJ Martins","year":"1982","unstructured":"Martins TJ, Mumby MC, Beavo JA. Purification and characterization of a cyclic GMP-stimulated cyclic nucleotide phosphodiesterase from bovine tissues. J Biol Chem. 1982;257:1973\u20139.","journal-title":"J Biol Chem"},{"key":"2031_CR6","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.neuropharm.2010.05.004","volume":"59","author":"V Lakics","year":"2010","unstructured":"Lakics V, Karran EH, Boess FG. Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues. Neuropharmacology. 2010;59:367\u201374.","journal-title":"Neuropharmacology"},{"key":"2031_CR7","doi-asserted-by":"publisher","first-page":"25782","DOI":"10.1074\/jbc.M109.017194","volume":"284","author":"C Russwurm","year":"2009","unstructured":"Russwurm C, Zoidl G, Koesling D, Russwurm M. Dual acylation of PDE2A splice variant 3: targeting to synaptic membranes. J Biol Chem. 2009;284:25782\u201390.","journal-title":"J Biol Chem"},{"key":"2031_CR8","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.neuroscience.2012.09.011","volume":"226","author":"DT Stephenson","year":"2012","unstructured":"Stephenson DT, Coskran TM, Kelly MP, Kleiman RJ, Morton D, O'Neill SM, et al. The distribution of phosphodiesterase 2A in the rat brain. Neuroscience. 2012;226:145\u201355.","journal-title":"Neuroscience"},{"key":"2031_CR9","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1369\/jhc.2009.953471","volume":"57","author":"DT Stephenson","year":"2009","unstructured":"Stephenson DT, Coskran TM, Wilhelms MB, Adamowicz WO, O'Donnell MM, Muravnick KB, et al. Immunohistochemical localization of phosphodiesterase 2A in multiple mammalian species. J Histochem Cytochem. 2009;57:933\u201349.","journal-title":"J Histochem Cytochem"},{"key":"2031_CR10","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.neuropharm.2004.07.040","volume":"47","author":"FG Boess","year":"2004","unstructured":"Boess FG, Hendrix M, van der Staay FJ, Erb C, Schreiber R, van Staveren W, et al. Inhibition of phosphodiesterase 2 increases neuronal cGMP, synaptic plasticity and memory performance. Neuropharmacology. 2004;47:1081\u201392.","journal-title":"Neuropharmacology"},{"key":"2031_CR11","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1038\/npp.2014.106","volume":"39","author":"E Bollen","year":"2014","unstructured":"Bollen E, Puzzo D, Rutten K, Privitera L, De Vry J, Vanmierlo T, et al. Improved long-term memory via enhancing cGMP-PKG signaling requires cAMP-PKA signaling. Neuropsychopharmacology. 2014;39:2497\u2013505.","journal-title":"Neuropsychopharmacology"},{"key":"2031_CR12","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s00213-015-4129-1","volume":"233","author":"LM Lueptow","year":"2016","unstructured":"Lueptow LM, Zhan CG, O\u2019Donnell JM. Cyclic GMP-mediated memory enhancement in the object recognition test by inhibitors of phosphodiesterase-2 in mice. Psychopharmacology (Berl). 2016;233:447\u201356.","journal-title":"Psychopharmacology (Berl)"},{"key":"2031_CR13","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.ejphar.2006.11.041","volume":"558","author":"K Rutten","year":"2007","unstructured":"Rutten K, Prickaerts J, Hendrix M, van der Staay FJ, Sik A, Blokland A. Time-dependent involvement of cAMP and cGMP in consolidation of object memory: studies using selective phosphodiesterase type 2, 4 and 5 inhibitors. Eur J Pharmacol. 2007;558:107\u201312.","journal-title":"Eur J Pharmacol"},{"key":"2031_CR14","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1038\/npp.2009.24","volume":"34","author":"K Rutten","year":"2009","unstructured":"Rutten K, Van Donkelaar EL, Ferrington L, Blokland A, Bollen E, Steinbusch HW, et al. Phosphodiesterase inhibitors enhance object memory independent of cerebral blood flow and glucose utilization in rats. Neuropsychopharmacology. 2009;34:1914\u201325.","journal-title":"Neuropsychopharmacology"},{"key":"2031_CR15","doi-asserted-by":"publisher","first-page":"21.","DOI":"10.3389\/fnmol.2019.00021","volume":"12","author":"S McQuown","year":"2019","unstructured":"McQuown S, Xia S, Baumg\u00e4rtel K, Barido R, Anderson G, Dyck B, et al. Phosphodiesterase 1b (PDE1B) regulates spatial and contextual memory in hippocampus. Front Mol Neurosci. 2019;12:21.","journal-title":"Front Mol Neurosci"},{"key":"2031_CR16","doi-asserted-by":"publisher","first-page":"6522","DOI":"10.1016\/j.bmcl.2013.10.014","volume":"23","author":"L Gomez","year":"2013","unstructured":"Gomez L, Breitenbucher JG. PDE2 inhibition: potential for the treatment of cognitive disorders. Bioorg Med Chem Lett. 2013;23:6522\u20137.","journal-title":"Bioorg Med Chem Lett"},{"key":"2031_CR17","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1021\/acs.jmedchem.6b01793","volume":"60","author":"L Gomez","year":"2017","unstructured":"Gomez L, Massari ME, Vickers T, Freestone G, Vernier W, Ly K, et al. Design and synthesis of novel and selective phosphodiesterase 2 (PDE2a) inhibitors for the treatment of memory disorders. J Med Chem. 2017;60:2037\u201351.","journal-title":"J Med Chem"},{"key":"2031_CR18","doi-asserted-by":"publisher","first-page":"5673","DOI":"10.1021\/acs.jmedchem.7b00397","volume":"60","author":"CJ Helal","year":"2017","unstructured":"Helal CJ, Arnold EP, Boyden TL, Chang C, Chappie TA, Fennell KF, et al. Application of structure-based design and parallel chemistry to identify a potent, selective, and brain penetrant phosphodiesterase 2A inhibitor. J Med Chem. 2017;60:5673\u201398.","journal-title":"J Med Chem"},{"key":"2031_CR19","doi-asserted-by":"publisher","first-page":"7658","DOI":"10.1021\/acs.jmedchem.7b00709","volume":"60","author":"S Mikami","year":"2017","unstructured":"Mikami S, Sasaki S, Asano Y, Ujikawa O, Fukumoto S, Nakashima K, et al. Discovery of an orally bioavailable, brain-penetrating, in vivo active phosphodiesterase 2A inhibitor lead series for the Treatment of cognitive disorders. J Med Chem. 2017;60:7658\u201376.","journal-title":"J Med Chem"},{"key":"2031_CR20","doi-asserted-by":"publisher","first-page":"3151","DOI":"10.1007\/s00213-014-3492-7","volume":"231","author":"JP Redrobe","year":"2014","unstructured":"Redrobe JP, J\u00f8rgensen M, Christoffersen CT, Montezinho LP, Bastlund JF, Carnerup M, et al. In vitro and in vivo characterisation of Lu AF64280, a novel, brain penetrant phosphodiesterase (PDE) 2A inhibitor: potential relevance to cognitive deficits in schizophrenia. Psychopharmacology (Berl). 2014;231:3151\u201367.","journal-title":"Psychopharmacology (Berl)"},{"key":"2031_CR21","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1021\/acsmedchemlett.8b00214","volume":"9","author":"SJ Stachel","year":"2018","unstructured":"Stachel SJ, Berger R, Nomland AB, Ginnetti AT, Paone DV, Wang D, et al. Structure-guided design and procognitive assessment of a potent and selective phosphodiesterase 2A inhibitor. ACS Med Chem Lett. 2018;9:815\u201320.","journal-title":"ACS Med Chem Lett"},{"key":"2031_CR22","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1016\/j.bmcl.2018.01.039","volume":"28","author":"SJ Stachel","year":"2018","unstructured":"Stachel SJ, Egbertson MS, Wai J, Machacek M, Toolan DM, Swestock J, et al. Indole acids as a novel PDE2 inhibitor chemotype that demonstrate pro-cognitive activity in multiple species. Bioorg Med Chem Lett. 2018;28:1122\u20136.","journal-title":"Bioorg Med Chem Lett"},{"key":"2031_CR23","doi-asserted-by":"publisher","first-page":"108414.","DOI":"10.1016\/j.neuropharm.2020.108414","volume":"184","author":"D Paes","year":"2021","unstructured":"Paes D, Xie K, Wheeler DG, Zook D, Prickaerts J, Peters M. Inhibition of PDE2 and PDE4 synergistically improves memory consolidation processes. Neuropharmacology. 2021;184:108414.","journal-title":"Neuropharmacology"},{"key":"2031_CR24","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1002\/syn.21840","volume":"69","author":"D Fernandez-Fernandez","year":"2015","unstructured":"Fernandez-Fernandez D, Rosenbrock H, Kroker KS. Inhibition of PDE2A, but not PDE9A, modulates presynaptic short-term plasticity measured by paired-pulse facilitation in the CA1 region of the hippocampus. Synapse. 2015;69:484\u201396.","journal-title":"Synapse"},{"key":"2031_CR25","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1124\/jpet.117.245506","volume":"365","author":"M Nakashima","year":"2018","unstructured":"Nakashima M, Imada H, Shiraishi E, Ito Y, Suzuki N, Miyamoto M, et al. Phosphodiesterase 2A inhibitor TAK-915 ameliorates cognitive impairments and social withdrawal in N-Methyl-d-aspartate receptor antagonist-induced rat models of schizophrenia. J Pharmacol Exp Ther. 2018;365:179\u201388.","journal-title":"J Pharmacol Exp Ther"},{"key":"2031_CR26","doi-asserted-by":"publisher","first-page":"112192.","DOI":"10.1016\/j.bbr.2019.112192","volume":"376","author":"M Nakashima","year":"2019","unstructured":"Nakashima M, Suzuki N, Shiraishi E, Iwashita H. TAK-915, a phosphodiesterase 2A inhibitor, ameliorates the cognitive impairment associated with aging in rodent models. Behav Brain Res. 2019;376:112192.","journal-title":"Behav Brain Res"},{"key":"2031_CR27","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1124\/jpet.118.255851","volume":"370","author":"G Gu","year":"2019","unstructured":"Gu G, Scott T, Yan Y, Warren N, Zhang A, Tabatabaei A, et al. Target engagement of a phosphodiesterase 2A inhibitor affecting long-term memory in the Rat. J Pharmacol Exp Ther. 2019;370:399\u2013407.","journal-title":"J Pharmacol Exp Ther"},{"key":"2031_CR28","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1002\/cne.10955","volume":"467","author":"WC Van Staveren","year":"2003","unstructured":"Van Staveren WC, Steinbusch HW, Markerink-Van Ittersum M, Repaske DR, Goy MF, Kotera J, et al. mRNA expression patterns of the cGMP-hydrolyzing phosphodiesterases types 2, 5, and 9 during development of the rat brain. J Comp Neurol. 2003;467:566\u201380.","journal-title":"J Comp Neurol"},{"key":"2031_CR29","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1124\/jpet.109.156729","volume":"331","author":"A Masood","year":"2009","unstructured":"Masood A, Huang Y, Hajjhussein H, Xiao L, Li H, Wang W, et al. Anxiolytic effects of phosphodiesterase-2 inhibitors associated with increased cGMP signaling. J Pharmacol Exp Ther. 2009;331:690\u20139.","journal-title":"J Pharmacol Exp Ther"},{"key":"2031_CR30","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1124\/jpet.108.137208","volume":"326","author":"A Masood","year":"2008","unstructured":"Masood A, Nadeem A, Mustafa SJ, O\u2019Donnell JM. Reversal of oxidative stress-induced anxiety by inhibition of phosphodiesterase-2 in mice. J Pharmacol Exp Ther. 2008;326:369\u201379.","journal-title":"J Pharmacol Exp Ther"},{"key":"2031_CR31","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1177\/0269881119832753","volume":"33","author":"L Chen","year":"2019","unstructured":"Chen L, Cui S, Yu H, Li G, Liu N, Wu Q, et al. Reduced phosphodiesterase-2 activity in the amygdala results in anxiolytic-like effects on behavior in mice. J Psychopharmacol. 2019;33:568\u201376.","journal-title":"J Psychopharmacol"},{"key":"2031_CR32","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.bbr.2014.03.042","volume":"268","author":"L Ding","year":"2014","unstructured":"Ding L, Zhang C, Masood A, Li J, Sun J, Nadeem A, et al. Protective effects of phosphodiesterase 2 inhibitor on depression- and anxiety-like behaviors: involvement of antioxidant and anti-apoptotic mechanisms. Behav Brain Res. 2014;268:150\u20138.","journal-title":"Behav Brain Res"},{"key":"2031_CR33","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/978-3-319-58811-7_12","volume":"17","author":"C Zhang","year":"2017","unstructured":"Zhang C, Lueptow LM, Zhang HT, O\u2019Donnell JM, Xu Y. The role of phosphodiesterase-2 in psychiatric and neurodegenerative disorders. Adv Neurobiol. 2017;17:307\u201347.","journal-title":"Adv Neurobiol"},{"key":"2031_CR34","doi-asserted-by":"publisher","first-page":"173768.","DOI":"10.1016\/j.ejphar.2020.173768","volume":"891","author":"L Chen","year":"2021","unstructured":"Chen L, Liu K, Wang Y, Liu N, Yao M, Hu J, et al. Phosphodiesterase-2 inhibitor reverses post-traumatic stress induced fear memory deficits and behavioral changes via cAMP\/cGMP pathway. Eur J Pharmacol. 2021;891:173768.","journal-title":"Eur J Pharmacol"},{"key":"2031_CR35","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1093\/ijnp\/pyac064","volume":"25","author":"X Pan","year":"2022","unstructured":"Pan X, Chen L, Shan C, Cai L, Wang Y, Chen Y, et al. Inhibition of phosphodiesterase 2 ameliorates post-traumatic stress-induced alcohol intake disorder by regulating cAMP\/cGMP signaling. Int J Neuropsychopharmacol. 2022;25:936\u201345.","journal-title":"Int J Neuropsychopharmacol"},{"key":"2031_CR36","doi-asserted-by":"publisher","first-page":"106393","DOI":"10.1016\/j.nbd.2023.106393","volume":"191","author":"S Delhaye","year":"2024","unstructured":"Delhaye S, Jarjat M, Boulksibat A, Sanchez C, Tempio A, Turtoi A, et al. Defects in AMPAR trafficking and microglia activation underlie socio-cognitive deficits associated to decreased expression of phosphodiesterase 2 a. Neurobiol Dis. 2024;191:106393.","journal-title":"Neurobiol Dis"},{"key":"2031_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-22193-0","volume":"8","author":"K Baumg\u00e4rtel","year":"2018","unstructured":"Baumg\u00e4rtel K, Green A, Hornberger D, Lapira J, Rex C, Wheeler DG, et al. PDE4D regulates spine plasticity and memory in the retrosplenial cortex. Sci Rep. 2018;8:3895. https:\/\/doi.org\/10.1038\/s41598-018-22193-0.","journal-title":"Sci Rep"},{"key":"2031_CR38","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1093\/cvr\/cvy030","volume":"114","author":"MR Assenza","year":"2018","unstructured":"Assenza MR, Barbagallo F, Barrios F, Cornacchione M, Campolo F, Vivarelli E, et al. Critical role of phosphodiesterase 2A in mouse congenital heart defects. Cardiovasc Res. 2018;114:830\u201345.","journal-title":"Cardiovasc Res"},{"key":"2031_CR39","doi-asserted-by":"publisher","first-page":"104855.","DOI":"10.1016\/j.neubiorev.2022.104855","volume":"141","author":"OY Chao","year":"2022","unstructured":"Chao OY, Nikolaus S, Yang YM, Huston JP. Neuronal circuitry for recognition memory of object and place in rodent models. Neurosci Biobehav Rev. 2022;141:104855.","journal-title":"Neurosci Biobehav Rev"},{"key":"2031_CR40","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/0023-9690(81)90020-5","volume":"12","author":"RGM Morris","year":"1981","unstructured":"Morris RGM. Spatial localization does not require the presence of local cues. Learning and Motivation. 1981;12:239\u201360.","journal-title":"Learning and Motivation"},{"key":"2031_CR41","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/hipo.22385","volume":"25","author":"TP Todd","year":"2015","unstructured":"Todd TP, Meyer HC, Bucci DJ. Contribution of the retrosplenial cortex to temporal discrimination learning. Hippocampus. 2015;25:137\u201341.","journal-title":"Hippocampus"},{"key":"2031_CR42","doi-asserted-by":"publisher","first-page":"2938","DOI":"10.1038\/npp.2014.154","volume":"39","author":"M Peters","year":"2014","unstructured":"Peters M, Bletsch M, Stanley J, Wheeler D, Scott R, Tully T. The PDE4 inhibitor HT-0712 improves hippocampus-dependent memory in aged mice. Neuropsychopharmacology. 2014;39:2938\u201348.","journal-title":"Neuropsychopharmacology"},{"key":"2031_CR43","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.brainres.2008.02.108","volume":"1216","author":"K Domek-Lopacinska","year":"2008","unstructured":"Domek-Lopacinska K, Strosznajder JB. The effect of selective inhibition of cyclic GMP hydrolyzing phosphodiesterases 2 and 5 on learning and memory processes and nitric oxide synthase activity in brain during aging. Brain Res. 2008;1216:68\u201377.","journal-title":"Brain Res"},{"key":"2031_CR44","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1523\/JNEUROSCI.4085-12.2014","volume":"34","author":"SA Heldt","year":"2014","unstructured":"Heldt SA, Zimmermann K, Parker K, Gaval M, Weinshenker D, Ressler KJ. BDNF deletion or TrkB impairment in amygdala inhibits both appetitive and aversive learning. J Neurosci. 2014;34:2444\u201350.","journal-title":"J Neurosci"},{"key":"2031_CR45","doi-asserted-by":"publisher","first-page":"3597","DOI":"10.1073\/pnas.1219593110","volume":"110","author":"ML Huff","year":"2013","unstructured":"Huff ML, Miller RL, Deisseroth K, Moorman DE, LaLumiere RT. Posttraining optogenetic manipulations of basolateral amygdala activity modulate consolidation of inhibitory avoidance memory in rats. Proc Natl Acad Sci. USA. 2013;110:3597\u2013602.","journal-title":"Proc Natl Acad Sci. USA"},{"key":"2031_CR46","doi-asserted-by":"publisher","first-page":"13057","DOI":"10.1523\/JNEUROSCI.3248-11.2011","volume":"31","author":"KA Maguschak","year":"2011","unstructured":"Maguschak KA, Ressler KJ. Wnt signaling in amygdala-dependent learning and memory. J Neurosci. 2011;31:13057\u201367.","journal-title":"J Neurosci"},{"key":"2031_CR47","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.neuroscience.2018.08.019","volume":"390","author":"T Paretkar","year":"2018","unstructured":"Paretkar T, Dimitrov E. The central amygdala corticotropin-releasing hormone (CRH) neurons modulation of anxiety-like behavior and hippocampus-dependent memory in mice. Neuroscience. 2018;390:187\u201397.","journal-title":"Neuroscience"},{"key":"2031_CR48","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.nlm.2014.01.006","volume":"109","author":"S Akkerman","year":"2014","unstructured":"Akkerman S, Blokland A, Prickaerts J. Mind the gap: delayed manifestation of long-term object memory improvement by phosphodiesterase inhibitors. Neurobiol Learn Mem. 2014;109:139\u201343.","journal-title":"Neurobiol Learn Mem"},{"key":"2031_CR49","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.neuropharm.2018.06.002","volume":"138","author":"W Gulisano","year":"2018","unstructured":"Gulisano W, Tropea MR, Arancio O, Palmeri A, Puzzo D. Sub-efficacious doses of phosphodiesterase 4 and 5 inhibitors improve memory in a mouse model of Alzheimer\u2019s disease. Neuropharmacology. 2018;138:151\u20139.","journal-title":"Neuropharmacology"},{"key":"2031_CR50","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/S0014-2999(01)01614-4","volume":"436","author":"J Prickaerts","year":"2002","unstructured":"Prickaerts J, de Vente J, Honig W, Steinbusch HW, Blokland A. cGMP, but not cAMP, in rat hippocampus is involved in early stages of object memory consolidation. Eur J Pharmacol. 2002;436:83\u201387.","journal-title":"Eur J Pharmacol"},{"key":"2031_CR51","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/S0092-8674(00)81904-2","volume":"88","author":"T Abel","year":"1997","unstructured":"Abel T, Nguyen PV, Barad M, Deuel TA, Kandel ER, Bourtchouladze R. Genetic demonstration of a role for PKA in the late phase of LTP and in hippocampus-based long-term memory. Cell. 1997;88:615\u201326.","journal-title":"Cell"},{"key":"2031_CR52","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.pneurobio.2006.06.004","volume":"79","author":"H Wang","year":"2006","unstructured":"Wang H, Hu Y, Tsien JZ. Molecular and systems mechanisms of memory consolidation and storage. Prog Neurobiol. 2006;79:123\u201335.","journal-title":"Prog Neurobiol"},{"key":"2031_CR53","doi-asserted-by":"publisher","first-page":"123.","DOI":"10.3389\/fnana.2014.00123","volume":"8","author":"Y Bernardinelli","year":"2014","unstructured":"Bernardinelli Y, Nikonenko I, Muller D. Structural plasticity: mechanisms and contribution to developmental psychiatric disorders. Front Neuroanat. 2014;8:123.","journal-title":"Front Neuroanat"},{"key":"2031_CR54","doi-asserted-by":"publisher","first-page":"E4142","DOI":"10.1073\/pnas.1311927110","volume":"110","author":"I Nikonenko","year":"2013","unstructured":"Nikonenko I, Nikonenko A, Mendez P, Michurina TV, Enikolopov G, Muller D. Nitric oxide mediates local activity-dependent excitatory synapse development. Proc Natl Acad Sci. USA. 2013;110:E4142\u20134151. https:\/\/doi.org\/10.1073\/pnas.1311927110","journal-title":"Proc Natl Acad Sci. USA"},{"key":"2031_CR55","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1089\/neu.2020.7364","volume":"38","author":"Q Wang","year":"2021","unstructured":"Wang Q, Mergia E, Koesling D, Mittmann T. Nitric oxide\/cyclic guanosine monophosphate signaling via guanylyl cyclase isoform 1 mediates early changes in synaptic transmission and brain edema formation after traumatic brain injury. J Neurotrauma. 2021;38:1689\u2013701.","journal-title":"J Neurotrauma"},{"key":"2031_CR56","first-page":"51","volume":"3","author":"MW Brown","year":"2002","unstructured":"Brown MW, Aggleton JP. Recognition memory: what are the roles of the perirhinal cortex and hippocampus? Nat Rev Neurosci. 2002;3:51\u201361.","journal-title":"Nat Rev Neurosci"},{"key":"2031_CR57","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1038\/s41431-020-0641-9","volume":"28","author":"D Doummar","year":"2020","unstructured":"Doummar D, Dentel C, Lyautey R, Metreau J, Keren B, Drouot N, et al. Biallelic PDE2A variants: a new cause of syndromic paroxysmal dyskinesia. Eur J Hum Genet. 2020;28:1403\u201313.","journal-title":"Eur J Hum Genet"},{"key":"2031_CR58","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1002\/mds.28023","volume":"35","author":"Z Haidar","year":"2020","unstructured":"Haidar Z, Jalkh N, Corbani S, Abou-Ghoch J, Fawaz A, Mehawej C, et al. A homozygous splicing mutation in PDE2A in a family with atypical rett syndrome. Mov Disord. 2020;35:896\u20139.","journal-title":"Mov Disord"},{"key":"2031_CR59","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1002\/mds.27286","volume":"33","author":"V Salpietro","year":"2018","unstructured":"Salpietro V, Perez-Due\u00f1as B, Nakashima K, San Antonio-Arce V, Manole A, Efthymiou S, et al. A homozygous loss-of-function mutation in PDE2A associated to early-onset hereditary chorea. Mov Disord. 2018;33:482\u20138.","journal-title":"Mov Disord"},{"key":"2031_CR60","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.cell.2015.02.004","volume":"160","author":"K Burkewitz","year":"2015","unstructured":"Burkewitz K, Morantte I, Weir H, Yeo R, Zhang Y, Huynh FK, et al. Neuronal CRTC-1 governs systemic mitochondrial metabolism and lifespan via a catecholamine signal. Cell. 2015;160:842\u201355.","journal-title":"Cell"},{"key":"2031_CR61","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/nature09706","volume":"470","author":"W Mair","year":"2011","unstructured":"Mair W, Morantte I, Rodrigues AP, Manning G, Montminy M, Shaw RJ, et al. Lifespan extension induced by AMPK and calcineurin is mediated by CRTC-1 and CREB. Nature. 2011;470:404\u20138.","journal-title":"Nature"},{"key":"2031_CR62","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1111\/j.1474-9726.2009.00495.x","volume":"8","author":"JH Hahm","year":"2009","unstructured":"Hahm JH, Kim S, Paik YK. Endogenous cGMP regulates adult longevity via the insulin signaling pathway in Caenorhabditis elegans. Aging Cell. 2009;8:473\u201383.","journal-title":"Aging Cell"},{"key":"2031_CR63","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1242\/dev.00330","volume":"130","author":"T Hirose","year":"2003","unstructured":"Hirose T, Nakano Y, Nagamatsu Y, Misumi T, Ohta H, Ohshima Y. Cyclic GMP-dependent protein kinase EGL-4 controls body size and lifespan in C elegans. Development. 2003;130:1089\u201399.","journal-title":"Development"},{"key":"2031_CR64","doi-asserted-by":"publisher","first-page":"30423","DOI":"10.1074\/jbc.M111.266379","volume":"286","author":"R Acin-Perez","year":"2011","unstructured":"Acin-Perez R, Russwurm M, G\u00fcnnewig K, Gertz M, Zoidl G, Ramos L, et al. A phosphodiesterase 2A isoform localized to mitochondria regulates respiration. J Biol Chem. 2011;286:30423\u201332.","journal-title":"J Biol Chem"},{"key":"2031_CR65","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1038\/s42003-020-01311-7","volume":"3","author":"MJ Lobo","year":"2020","unstructured":"Lobo MJ, Reverte-Salisa L, Chao YC, Koschinski A, Gesellchen F, Subramaniam G, et al. Phosphodiesterase 2A2 regulates mitochondria clearance through Parkin-dependent mitophagy. Commun Biol. 2020;3:596.","journal-title":"Commun Biol"},{"key":"2031_CR66","doi-asserted-by":"publisher","first-page":"111772","DOI":"10.1016\/j.celrep.2022.111772","volume":"41","author":"M Rozenfeld","year":"2022","unstructured":"Rozenfeld M, Azoulay IS, Ben Kasus Nissim T, Stavsky A, Melamed M, Stutzmann G, et al. Essential role of the mitochondrial Na(+)\/Ca(2+) exchanger NCLX in mediating PDE2-dependent neuronal survival and learning. Cell Rep. 2022;41:111772.","journal-title":"Cell Rep"},{"key":"2031_CR67","doi-asserted-by":"publisher","first-page":"432","DOI":"10.3389\/fncel.2019.00432","volume":"13","author":"L Ruan","year":"2019","unstructured":"Ruan L, Du K, Tao M, Shan C, Ye R, Tang Y, et al. Phosphodiesterase-2 inhibitor bay 60-7550 ameliorates abeta-induced cognitive and memory impairment via regulation of the HPA axis. Front Cell Neurosci. 2019;13:432.","journal-title":"Front Cell Neurosci"},{"key":"2031_CR68","doi-asserted-by":"publisher","first-page":"794458.","DOI":"10.3389\/fphar.2021.794458","volume":"12","author":"J Shi","year":"2021","unstructured":"Shi J, Li Y, Zhang Y, Chen J, Gao J, Zhang T, et al. Baicalein ameliorates abeta-induced memory deficits and neuronal atrophy via inhibition of PDE2 and PDE4. Front Pharmacol. 2021;12:794458.","journal-title":"Front Pharmacol"},{"key":"2031_CR69","doi-asserted-by":"publisher","first-page":"17.","DOI":"10.1186\/s13195-017-0245-y","volume":"9","author":"R Hesse","year":"2017","unstructured":"Hesse R, Lausser L, Gummert P, Schmid F, Wahler A, Schnack C, et al. Reduced cGMP levels in CSF of AD patients correlate with severity of dementia and current depression. Alzheimers Res Ther. 2017;9:17.","journal-title":"Alzheimers Res Ther"},{"key":"2031_CR70","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1111\/nan.12203","volume":"41","author":"A Ugarte","year":"2015","unstructured":"Ugarte A, Gil-Bea F, Garc\u00eda-Barroso C, Cedazo-Minguez \u00c1, Ram\u00edrez MJ, Franco R, et al. Decreased levels of guanosine 3\u2019, 5\u2019-monophosphate (cGMP) in cerebrospinal fluid (CSF) are associated with cognitive decline and amyloid pathology in Alzheimer\u2019s disease. Neuropathol Appl Neurobiol. 2015;41:471\u201382.","journal-title":"Neuropathol Appl Neurobiol"},{"key":"2031_CR71","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1124\/jpet.119.260059","volume":"371","author":"H Rosenbrock","year":"2019","unstructured":"Rosenbrock H, Giovannini R, Sch\u00e4nzle G, Koros E, Runge F, Fuchs H, et al. The novel phosphodiesterase 9A inhibitor BI 409306 increases cyclic guanosine monophosphate levels in the Brain, promotes synaptic plasticity, and enhances memory function in rodents. J Pharmacol Exp Ther. 2019;371:633\u201341.","journal-title":"J Pharmacol Exp Ther"},{"key":"2031_CR72","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.cell.2011.06.013","volume":"146","author":"JC Darnell","year":"2011","unstructured":"Darnell JC, Van Driesche SJ, Zhang C, Hung KY, Mele A, Fraser CE, et al. FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism. Cell. 2011;146:247\u201361.","journal-title":"Cell"},{"key":"2031_CR73","doi-asserted-by":"publisher","first-page":"6344","DOI":"10.1093\/nar\/gky267","volume":"46","author":"T Maurin","year":"2018","unstructured":"Maurin T, Lebrigand K, Castagnola S, Paquet A, Jarjat M, Popa A, et al. HITS-CLIP in various brain areas reveals new targets and new modalities of RNA binding by fragile X mental retardation protein. Nucleic Acids Res. 2018;46:6344\u201355.","journal-title":"Nucleic Acids Res"},{"key":"2031_CR74","doi-asserted-by":"publisher","first-page":"3241","DOI":"10.1093\/cercor\/bhy192","volume":"29","author":"T Maurin","year":"2019","unstructured":"Maurin T, Melancia F, Jarjat M, Castro L, Costa L, Delhaye S, et al. Involvement of phosphodiesterase 2A activity in the pathophysiology of fragile X syndrome. Cereb Cortex. 2019;29:3241\u201352.","journal-title":"Cereb Cortex"},{"key":"2031_CR75","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-022-01885-2","volume":"12","author":"S Schiavi","year":"2022","unstructured":"Schiavi S, Carbone E, Melancia F, di Masi A, Jarjat M, Brau F, et al. Phosphodiesterase 2A inhibition corrects the aberrant behavioral traits observed in genetic and environmental preclinical models of autism spectrum disorder. Transl Psychiatry. 2022;12:119.","journal-title":"Transl Psychiatry"},{"key":"2031_CR76","doi-asserted-by":"publisher","first-page":"4570","DOI":"10.1038\/s41380-020-00997-9","volume":"26","author":"S Delhaye","year":"2021","unstructured":"Delhaye S, Bardoni B. Role of phosphodiesterases in the pathophysiology of neurodevelopmental disorders. Mol Psychiatry. 2021;26:4570\u201382.","journal-title":"Mol Psychiatry"}],"container-title":["Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41386-024-02031-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41386-024-02031-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41386-024-02031-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T09:25:15Z","timestamp":1742203515000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41386-024-02031-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,27]]},"references-count":76,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["2031"],"URL":"https:\/\/doi.org\/10.1038\/s41386-024-02031-w","relation":{},"ISSN":["0893-133X","1740-634X"],"issn-type":[{"type":"print","value":"0893-133X"},{"type":"electronic","value":"1740-634X"}],"subject":[],"published":{"date-parts":[[2024,11,27]]},"assertion":[{"value":"1 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors are past employees of Dart Neuroscience, LLC. MP has consulted for companies involved with the development of PDE inhibitors, including Dart Neuroscience, LLC. All other authors declare no financial conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}